Lin Mao, Liang Shu-Zhen, Wang Xiao-Hua, Liang Ying-Qing, Zhang Ming-Jie, Niu Li-Zhi, Chen Ji-Bing, Li Hai-Bo, Xu Ke-Cheng
Department of Biological Treatment Center, Fuda Cancer Hospital, Jinan University School of Medicine, Jinan, China.
Fuda Cancer Institute, Guangzhou, China.
Immunol Res. 2017 Aug;65(4):880-887. doi: 10.1007/s12026-017-8927-x.
In this study, the safety and clinical efficacy of cryosurgery combined with allogenic NK cell immunotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) were evaluated. From July 2016 to March 2017, we enrolled 60 patients who met the enrollment criteria and divided them into two groups: (1) the simple cryoablation group (n = 30) and (2) the cryoablation combined with allogenic NK cell group (n = 30). The changes in immune function, quality of life, and clinical response were evaluated. We found that allogenic NK cells combined with cryosurgical treatment for advanced NSCLC have a synergistic effect, which not only enhancing the immune function of patients, improving the quality of life, and significantly increasing the response rate (RR) and disease control rate (DCR) compared to cryoablation group. This study is the first clinical trial of allogenic NK cells combined with cryosurgery for the treatment of advanced NSCLC and preliminaily its safety and efficacy.
本研究评估了冷冻消融联合异基因自然杀伤（NK）细胞免疫疗法治疗晚期非小细胞肺癌（NSCLC）的安全性和临床疗效。2016年7月至2017年3月，我们纳入了60例符合纳入标准的患者，并将他们分为两组：（1）单纯冷冻消融组（n = 30）和（2）冷冻消融联合异基因NK细胞组（n = 30）。评估了免疫功能、生活质量和临床反应的变化。我们发现，异基因NK细胞联合冷冻消融治疗晚期NSCLC具有协同作用，与冷冻消融组相比，不仅增强了患者的免疫功能，改善了生活质量，还显著提高了缓解率（RR）和疾病控制率（DCR）。本研究是异基因NK细胞联合冷冻消融治疗晚期NSCLC的首个临床试验，并初步验证了其安全性和疗效。
